Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03105817
Other study ID # LIB 09/2015
Secondary ID
Status Completed
Phase N/A
First received March 27, 2017
Last updated April 3, 2017
Start date February 1, 2016
Est. completion date August 14, 2016

Study information

Verified date March 2017
Source Hospital Universitario Infanta Leonor
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In post-dilution haemodiafiltration only synthetic membranes have been used to date.

The allergy problems described with these membranes require the development of other membranes capable of performing this treatment. We describe in vivo performance and behaviour of an asymmetric cellulose triacetate(ATA™) membrane, to identify its depurative effectiveness and ease of use in clinical practice, as well as evaluate its biocompatibility in a single haemodialysis session (acute biocompatibility) and after one month of treatment (chronic).


Description:

An interventional study was performed in 3 hemodialysis hospital units (La Princesa University Hospital, Príncipe de Asturias University Hospital and Infanta Leonor University Hospital, Community of Madrid, Spain) in which the usual dialyzer that each patient had for OLHDF was replaced with the Solacea™ dialyzer keeping the rest of the parameters unchanged. The study (LIB 09/2015) was reviewed and approved by the CEIC of the Príncipe de Asturias University Hospital.

- Design of the study Each patient underwent 12 sessions of haemodialysis with the usual schedule and monitor: 5008 of Fresenius (n=14), AK200US (n=5) and Artis of Gambro (n=3) and DBB007 of Nikkiso (n=1) all suitable for OLHDF, although with different convective transport control systems. The nursing staff connected the automatic OLHDF system. In the case where the system was Ultracontrol® (Gambro monitors) if alarm of PTM> 300 mmHg or system pressure (PSist)> 700 mmHg appeared and were not solved, Ultracontrol® would be withdrawn and the pressure-control system would be used.

- Data to be collected:

1. Demographic and dialysis data

- Demographic: sex, age, underlying disease, time in OLHDF, type of vascular access: fistula (AFV) and catheter (CT).

- Dialysis Data: Monitor, dialysis fluid composition, sodium conductivity and bicarbonate concentration, dialysis fluid flow (Qd, ml min), liquid temperature, heparin type and dosage.

- Each dialysis session: effective time (TE, min), blood flow (Qb, ml min), ultra-filtrated volume to achieve dry weight (UF, l/session), Vinf (l/session), infusion rate, (Qi, ml/min) Kt (l / session), maximum PTM and maximum Psist in Ultracontrol® (mmHg) and the technical complications, alarms and coagulation problems of the system that may appear.

The filtration fraction (FF) was calculated as the percentage of Qi relative to Qb. The convective volume (Vconv) was defined as the total ultra-filtrated volume, which is the sum of VI and UF.7

2. Analytical determinations

1. Blood

- On the first and last day of the study pre-dialysis samples were taken for the measurement of monocytes, IL-6 and IL-1β.

- On the interval day of the first week, 3 blood samples were taken: 1st) at the beginning (CI), 2nd) at 30 min (CM) and the 3rd) at the end of the dialysis session (CP).

In CI and CP the following parameters were measured: haemoglobin, proteins and albumin, urea, phosphorus, creatinine, uric acid, β2-microglobulin, myoglobin and retinol transport protein (RTP).

Leukocytes, platelets, C3a and C5a were quantified in CI and CM.

--- Laboratory determinations

- General biochemical data: haemoglobin, proteins, albumin, urea, phosphorus, reactive protein C (PCR), creatinine and uric acid, β2-microglobulin, myoglobin, and (RTP) were determined with the usual analyser of each hospital.

- Determinations of monocytes, complement, IL-6 and IL-1β were performed in the laboratory of the University of Alcalá:

- Activation of plasma complement using a sandwich ELISA: Determination of C3a and C5a activation was performed on platelet rich plasma samples using commercially available ELISA kits C3a Elabscience (Wuhan, P.R. China) and ELISA C5a RayBiotech (Norcross, Georgia).

- Determination of interleukin concentration in serum using a sandwich ELISA: IL-6 and IL-1β concentrations were measured in serum samples obtained from whole blood and stored at -80 ° C until use. Both kits used were supplied by Abcam (Cambridge, UK)

- Determination of monocyte subpopulations: The different subpopulations of circulating monocytes in peripheral blood were identified by flow cytometry (FACSCalibur™, Becton Dickinson, San Jose, CA, USA). First of all, the monocyte population was selected according to size (FSC/forward scatter) and granularity (SSC/side scatter) and then the different subpopulations were selected by double immunofluorescence according to staining with the anti-CD14 conjugated Tricolor (monoclonal antibodies TuK4) and anti-CD16 conjugated FITC (monoclonal antibodies 3G8). Both antibodies and their respective isotype controls were purchased from Life Technologies Invitrogen (California, USA). The analysis was performed with the Cyflogic program.

- Calculations The percentages of reduction (RR) were calculated with the formula: RR (%) = [(Cpre - Cpos) / Cpre] x 100, where Cpre and Cpos are the concentrations of the analysed substances pre- and post-dialysis.

For protein bound substances and β2-microglobulin concentrations at the end of the session were corrected for haemoconcentration by a correction factor (FC) based on plasma protein concentration (PT):

FC = PTpre / PTpos, where PTpre and PTpos are the total concentration of proteins pre-dialysis and post-dialysis.

--- Statistical analysis All data was collected in a database (SPSS version 15). Each value was obtained with the average of the values obtained in the different sessions or analytical determinations.

For the statistical analysis, descriptive tools were used, showing the average (standard deviation), median, quartiles or percentages as appropriate. For the comparison of two independent continuous variables, the Student t test for paired samples was used. For the comparison of more than two quantitative variables the ANOVA test was used. The p <0.05 was considered statistically significant.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date August 14, 2016
Est. primary completion date July 10, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion

- Criteria:being over 18 years old, being treated with OLHDF for more than 4 weeks with 3 weekly sessions and sign an informed consent form.

Exclusion Criteria:

- pregnancy and illness that would make the patient's death predictable in less than 4 weeks.

Study Design


Intervention

Device:
Asymmetric cellulose triacetate (ATA™)
Each patient underwent 12 sessions of haemodialysis with the usual schedule, changing the usual dialyzer

Locations

Country Name City State
Spain Marta Albalate Ramón Madrid

Sponsors (1)

Lead Sponsor Collaborator
Hospital Universitario Infanta Leonor

Country where clinical trial is conducted

Spain, 

References & Publications (5)

Maduell F, Navarro V, Hernández-Jaras J, Calvo C. [Comparison of dialyzers in on-line hemodiafiltration]. Nefrologia. 2000 May-Jun;20(3):269-76. Spanish. — View Citation

Mineshima M. Optimal Design of Dialyzers. Contrib Nephrol. 2017;189:204-209. Epub 2016 Dec 12. — View Citation

Sánchez-Villanueva RJ, González E, Quirce S, Díaz R, Alvarez L, Menéndez D, Rodríguez-Gayo L, Bajo MA, Selgas R. Hypersensitivity reactions to synthetic haemodialysis membranes. Nefrologia. 2014;34(4):520-5. doi: 10.3265/Nefrologia.pre2014.May.12552. Engl — View Citation

Sunohara T, Masuda T. Cellulose triacetate as a high-performance membrane. Contrib Nephrol. 2011;173:156-63. doi: 10.1159/000329055. Epub 2011 Aug 8. Review. — View Citation

Sunohara T, Masuda T. Fundamental Characteristics of the Newly Developed ATA™ Membrane Dialyzer. Contrib Nephrol. 2017;189:215-221. Epub 2016 Dec 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Performance of asymmetric cellulose triacetate (ATA™) Describing in vivo depurative efficacy of asymmetric cellulose triacetate (ATA™) measuring Kt, infusion volumen and clearance of RR of different molecules One month
Primary Biocompatibility of asymmetric cellulose triacetate (ATA™) Studying its acute (measuring complement and leukocites) and chronic (measuring monocytes subpopulationsand interleukines) One month
Primary Clinical behaviour of ATA Studuying alarm or clínical problemas related with dialyzer One month
See also
  Status Clinical Trial Phase
Completed NCT05700851 - Immuno-nutrition Supplementation in Haemodialysis N/A
Recruiting NCT02616627 - Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Completed NCT01464190 - A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients Phase 3
Recruiting NCT06040281 - Smart and Fit for Kidney Transplantation N/A
Active, not recruiting NCT03535922 - Evaluation of Routinely Measured Patient-reported Outcomes in Hemodialysis Care N/A
Completed NCT04622709 - Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis Phase 2
Completed NCT04585607 - Potential Benefits of Expanded Hemodialysis in Prevention of Sarcopenia Phase 4
Completed NCT03182699 - Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients Phase 4
Completed NCT03942744 - The Effect of High-flux Hemodialysis and On-line Hemodiafiltration on Endothelial Function. N/A
Completed NCT04549597 - Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia Phase 4
Recruiting NCT04659525 - Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia Phase 4
Completed NCT04125537 - Pathways Project: Kidney Supportive Care
Recruiting NCT03347773 - Oral Nutritional Supplement Intervention Among Hemodialysis Patients With Sarcopenic Obesity N/A
Recruiting NCT04397653 - Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients Phase 4
Active, not recruiting NCT03938285 - Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Removal N/A
Completed NCT03525223 - Modulation of Tissue Sodium in Hemodialysis Patients N/A
Completed NCT01324128 - A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients Phase 3
Not yet recruiting NCT04600193 - a Randomized Controlled Trial of the Intake of Organic and Inorganic Phosphate in Peritoneal Dialysis Patients N/A
Not yet recruiting NCT06225544 - Lumasiran in Hyperoxalaemic Patients on Haemodialysis Phase 2
Recruiting NCT05209880 - Advance Care Planning in the Emergency Department N/A